1. Home
  2. MRVI vs RPC Comparison

MRVI vs RPC Comparison

Compare MRVI & RPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$6.59

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

RPC

Ridgepost Capital Inc. Class A Common Stock

N/A

Current Price

$8.41

Market Cap

905.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MRVI
RPC
Founded
2014
1992
Country
United States
United States
Employees
N/A
326
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
905.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
MRVI
RPC
Price
$6.59
$8.41
Analyst Decision
Buy
Buy
Analyst Count
4
1
Target Price
$4.13
$11.00
AVG Volume (30 Days)
2.9M
472.5K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
1.96%
EPS Growth
14.29
N/A
EPS
N/A
N/A
Revenue
$185,743,000.00
N/A
Revenue This Year
$12.54
$16.82
Revenue Next Year
$7.87
$15.80
P/E Ratio
N/A
$53.06
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$6.79
52 Week High
$7.44
$9.32

Technical Indicators

Market Signals
Indicator
MRVI
RPC
Relative Strength Index (RSI) 54.97 55.48
Support Level $3.36 $7.54
Resistance Level N/A $8.78
Average True Range (ATR) 0.38 0.34
MACD -0.07 0.05
Stochastic Oscillator 45.65 69.53

Price Performance

Historical Comparison
MRVI
RPC

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

About RPC Ridgepost Capital Inc. Class A Common Stock

Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

Share on Social Networks: